Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel) Following Induction and Consolida-Tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Next Previous
Trial Profile

Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel) Following Induction and Consolida-Tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Feb 2021 Results (n=75) of RATIFY, AMLSG 16-10, AMLSG 07-04 and AMLSG 11-08 trials assessing clonal evolution of FLT3-ITD positive AML in patients with relapsed and refractory disease who were treated with intensive chemotherapy in combination with the multi-kinase inhibitor midostaurin, published in the Blood
    • 06 Dec 2016 Results assessing minimal residual disease monitoring in Acute Myeloid Leukemia study group (AML HD93, NCT00146120, NCT00151255, NCT00151242, NCT00850382 and NCT02013648 trials) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top